Arjun Balar, MD
Vice President - Global Clinical Development; Loxo Oncology at Eli Lilly. Former Director of the genitourinary medical oncology program and Medical Director of the Clinical Trials Office at NYU Langone’s Perlmutter Cancer Center. Associate Professor, Department of Medicine at NYU Grossman School of Medicine.
Pedro Barata, MD, MSc
Pedro C. Barata, MD, MSc is an Associate Professor of Medicine at Case Western University and the Director of Clinical Genitourinary Medical Oncology Research Program at University Hospitals Seidman Cancer Center, Cleveland, Ohio. Dr. Barata is a medical oncologist and a clinical trialist and his research interests include molecular profiling of tumors and genomic-based therapies for genitourinary tumors. He earned his medical degree from the New University of Lisbon in 2009 and completed his medical oncology training in 2016. After completion of his fellowship, he was invited to join the genitourinary group at Taussig Cancer Center, where he worked as a clinical fellow in genitourinary malignancies. Dr. Barata moved to Tulane University to continue his clinical and research work in the GU field and to help expand the genitourinary program offered at Tulane Cancer Center, with a focus on clinical trials. In September of 2022, Dr Barata moved to his current position at the University Hospitals Seidman Cancer Center in Cleveland, Ohio. Dr. Barata has authored or co-authored dozens of publications in high-quality and pubmed-indexed journals. In addition, he has presented multiple abstracts at important national and international meetings and has won multiple prestigious awards, including the Tulane Career Development Award, Clinical Sciences (2021). He serves as a reviewer for prestigious peer-reviewed journals, such as JAMA Oncology, Cancer, Lancet Oncology, ASCO and Journal of Global Oncology and is the Prostate Section Editor of the Oncologist journal and a member of the Editorial Board of the Translation Oncology.
Benjamin Brucker, MD
Associate Professor Department of Urology and Associate Professor Department of Obstetrics and Gynecology at NYU Grossman School of Medicine. Director of the Female Pelvic Medicine and Reconstructive Surgery Program and Neuro-Urology, and Director of the Female Pelvic Medicine Fellowship Program, NYU Langone Health, New York, New York
Jeremie Calais, MD, MSc
Assistant Professor and Director of the Clinical Research Program of the Ahmanson Translational Theranostics Division of the Department of Molecular and Medical Pharmacology at UCLA. He is also a member of the Jonsson Comprehensive Cancer Center and the UCLA Institute of Urologic Oncology, UCLA Health
Thenappan Chandrasekar, MD
Assistant Professor of Urologic Oncology & the Director of Abington-Jefferson Urology at Thomas Jefferson University Philadelphia, Pennsylvania
Sam S. Chang MD, MBA
Dr. Chang is a Professor, Department of Urology and the Patricia and Rodes Hart Professor of Urologic Surgery. He is the Chief Surgical Officer at the Vanderbilt Ingram Cancer Center and the Chief Division of Urologic Oncology. He alos is the Assistant Secretary of the American Urological Association and Chair of the American Board of Urology Examination Committee responsible for board certification in the U.S
Matthew R. Cooperberg, MD, MPH
Dr. Cooperberg is a Professor of Urology; Epidemiology & Biostatistics and the Helen Diller Family Chair in Urology. He is part of the multidisciplinary urologic oncology team of the UCSF Helen Diller Family Comprehensive Cancer Center, located primarily at the Mission Bay campus. He also maintains privileges at San Francisco General Hospital.
Bishoy Morris Faltas, MD
Dr. Bishoy Faltas is the Director of Bladder Cancer Research at the Englander Institute for Precision Medicine. He is the Gellert Family-John P. Leonard, MD Research Scholar in Hematology and Medical Oncology, and Assistant Professor of Medicine, Cell and Developmental Biology at Weill Cornell Medicine
Karim Fizazi, MD, PhD
A medical oncologist at Gustave Roussy, and a full professor in Oncology at the University of Paris-Saclay in Villejuif, France. He is the President of the French Groupe d’Etude des Tumeurs Genito-Urinaires (GETUG) and the President of the French Study Group of Carcinomas of Unknown Primary (GEFCAPI). Prof. Fizazi is associate editor of European Journal of Cancer and consulting editor of European Urology.
Daniel George, MD
Professor of Medicine and Surgery, Divisions of Medical Oncology and Urology in the Duke University School of Medicine and leads the Duke Prostate and Urologic Cancer Center. He also has appointments in the Duke Clinical Research Institute and the Duke Cancer Institute where he is the Director of Genitourinary (GU) Oncology. Daniel George has led the Duke site for the Department of Defense (DOD) Prostate Cancer Clinical Trials Consortium since 2006.
Hanan Goldberg, MD, MSc
Assistant professor at SUNY Upstate Medical University in Syracuse, New York. Dr. Goldberg completed a three year fellowship in Uro-Oncology with the department of surgical oncology in the division of Urology at the Princess Margaret Hospital, University Health Network at the University of Toronto in Toronto, Canada.
Petros Grivas, MD, PhD
Petros Grivas, MD, Ph.D. is a Professor and the Clinical Director of the Genitourinary Cancers Program at the University of Washington, and an Associate Member of the Clinical Research Division at the Fred Hutchinson Cancer Research Center with expertise in genitourinary cancers such as bladder cancer, prostate cancer, and testis cancer.
Michael Hofman, MBBS (Hons), FRACP, FAANMS, FICIS
Professor Michael Hofman is a nuclear medicine physician and physician-scientist at the Peter MacCallum Cancer Centre in Melbourne. He currently serves as the vice chair of the oncology program for the SNMMI. He is an associate editor for several journals including the international editorial committee of the Journal of Nuclear Medicine and the nuclear medicine subsection editor for Cancer Imaging. Prof Hofman is a member of the PMCC Research Leadership Group and is the Program Director of the newly established Prostate Theranostics and Imaging Centre of Excellence (ProsTIC).
Ashish Kamat, MD, MBBS
Professor of Urology and Cancer Research and Wayne B. Duddleston Professor of Cancer Research at MD Anderson Cancer Center in Houston, Texas. Dr. Kamat serves as President of International Bladder Cancer Group, (IBCG), and Co-President of International Bladder Cancer Network. He is a graduate of the AUA Leadership Program.
Dr. Kamat is Chair, Bladder Cancer Think Tank (2015), Chair, Bladder Cancer Task Force for SITC, actively participates in various global urologic efforts, and serves on the board of regional and national societies for Urology.
Thomas Keane, MBBCh, FRCSI, FACS
Professor and Chairman of the Department of Urology at the Medical University of South Carolina, Charleston, South Carolina. He holds a U.S. patent for BNCT in prostate cancer and sphingolipid derivatives and their use.
Zachary Klaassen, MD, MSc
Zachary Klaassen, MD, MSc is a board certified urologist specializing in Urologic Oncology at the Georgia Cancer Center at the Medical College of Georgia - Augusta University. Director of Clinical Urologic Research, Ronald W. Lewis, MD Endowed Chair for Urologic Education, Residency Program Director and Assistant Professor of Urology, Department of Surgery, Augusta University Health
Badrinath Konety, MD, MBBS, MBA
Dr. Badrinath Konety serves as the Henry P. Russe, MD, Dean of Rush Medical College and senior vice president, clinical affairs, for Rush University System for Health, Chicago, Illinois
A board-certified urologist, Konety is a fellow of the American College of Surgeons and the American Urologic Association. He also is secretary/treasurer of the Societe Internationale d’Urologie (US Section). He has published more than 120 peer-reviewed articles, as well as a number of book chapters and review articles. He is on the editorial board of several journals and is a member of multiple guideline panels. He has been awarded a number of grants from the DOD, NCI, ACS and CDC. He is recognized as an expert on prostate and bladder cancer. He has given presentations on a wide range of urologic oncology topics nationally and internationally. He has been listed on the Best Doctors in America since 2009.
Phillip Koo, MD
Division Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Arizona. Prior to this, he was Chief of Nuclear Medicine and Associate Professor of Radiology at the University of Colorado School of Medicine. He is a diplomate of both the American Board of Radiology (ABR) and American Board of Nuclear Medicine and is the Chair of the Quality and Evidence Committee for the Society of Nuclear Medicine and Molecular Imaging.
Stephen R. Kraus, MD, MBA, FACS
Professor and Interim Chairman of the Department of Urology at the University of Texas Health Science Center at San Antonio where he heads the Division of Female Urology, Neuro - Urology and Voiding Dysfunction. He is the Holder of the Hans H. Scharringhausen Professorship in Urology, and a Fellow of the American College of Surgeons, Dr. Kraus is also a member of: the American Urological Association, the Geriatric Urology Society, the American Urogynecologic Society, the International Continence Society and the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU).
Janet Kukreja, MD, MPH
Assistant Professor, Surgery-Urology, Urologic Oncologist, University of Colorado Anschutz Medical Campus
Sumanta (Monty) Kumar Pal, MD
Internationally recognized leader in the area of genitourinary cancers, including kidney, bladder, and prostate cancer. He is the Co-director of City of Hope's Kidney Cancer Program and is the head of the kidney and bladder cancer disease. Dr. Pal sits on the Editorial Board for clinical genitourinary cancer and is a reviewer for multiple journals including The Journal of Clinical Oncology, The Journal of Urology, European Urology, and many others.
Alexander Kutikov, MD, FACS
Chief of the Division of Urology and Urologic Oncology, Professor, Department of Surgical Oncology, Roberta R. Scheller Chair in Urologic Oncology, Kidney, Bladder, and Prostate Cancer TRDG Member, American Urological Association's Urology Care Foundation, Prostate Health Committee Panel Member, Fox Chase Cancer Center, Temple Health
Jaime Landman, MD
Director of the UCI Health Center for Urological Care, is an internationally recognized urologist and expert in diseases and conditions of the kidneys, including kidney stones and benign and malignant tumors. He is experienced in all forms of minimally invasive kidney surgery, including robot-assisted surgery and percutaneous cryoablation. Dr. Landman, who founded the UCI Health Ablative Oncology Center, has performed more than 2,000 advanced minimally invasive kidney procedures. He is dedicated to improving the techniques and technology associated with minimally invasive surgery.
Roger Li, MD
Genitourinary Oncology, at Moffitt Cancer Center in Tampa, FL
Justin Matulay, MD
Genitourinary surgical oncologist at Levine Cancer Institute. Dr. Matulay specializes in research and surgical treatment of urinary system cancers and brings a wealth of expertise to patients and the region. Charlotte, North Carolina
Todd Morgan, MD
Professor of Urology, Chief, Division of Urologic Oncology, Urological Surgical Oncologist, The University of Michigan
Alicia Morgans, MD, MPH
Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, Massachusetts. She is a clinician and physician investigator specializing in investigating complications of systemic therapy for prostate cancer survivors. She has expertise in clinical trials and patient-reported outcome measures, and as well as incorporating patient preferences and beliefs into clinical decision making.
Lorelei Mucci, ScD, MPH
Professor of Epidemiology and Director of the Cancer Epidemiology and Cancer Prevention Program within the Department of Epidemiology at the Harvard T.H. Chan School of Public Health (HSPH). In addition, Dr. Mucci is the Leader of the Cancer Epidemiology Program at the Dana-Farber/Harvard Cancer Center.
Diane Newman, DNP, ANP-BC, FAAN
Urologic Nurse Practitioner, Adjunct Professor of Urology in Surgery, Research Investigator Senior, Perelman School of Medicine, University of Pennsylvania and Former Co-Director of the Penn Center for Continence and Pelvic Health. She is the author of several books. The most recent is as lead editor of the 1st edition of the SUNA Core Curriculum for Urologic Nursing and of Clinical Application of Urologic Catheters, Devices and Products.
William K. Oh, MD
William K. Oh, MD is an internationally recognized genitourinary (GU) oncologist with expertise in the use of systemic treatments for prostate cancer and he serves as the Chief Medical Officer (CMO), of the Prostate Cancer Foundation (PCF). Dr. Oh joins the PCF from Sema4, where he served as CMO of the patient-centered health intelligence company focused on precision medicine. He also served for over a decade as Chief of the Division of Hematology and Medical Oncology at the Icahn School of Medicine, Ezra Greenspan Professor of Clinical Cancer Research, and Deputy Director of the NCI-designated Tisch Cancer Institute at Mount Sinai.
Zhamshid Okhunov, MD
Department of Urology, University of California, Irvine
Charles Ryan, MD
Charles J. Ryan, MD is the President and Chief Executive Officer of The Prostate Cancer Foundation (PCF), the world’s leading philanthropic organization dedicated to funding life-saving prostate cancer research. Charles (Chuck) J. Ryan is an internationally recognized genitourinary (GU) oncologist with expertise in the biology and treatment of advanced prostate cancer. Dr. Ryan joins the PCF from the University of Minnesota, Minneapolis, where he served as Director of the Hematology, Oncology, and Transplantation Division in the Department of Medicine. He also served as Associate Director for Clinical Research in the Masonic Cancer Center and held the B.J. Kennedy Chair in Clinical Medical Oncology.
Neal Shore, MD, FACS
Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. He serves on the Executive Boards of: Society of Urologic Oncology Board, Bladder Cancer Advocacy Network, and is Immediate Past President, Large Urology Group Practice Association. He is a founder for both: CUSP Clinical Trials Consortium, as well as for DASHKO, large urology practices data registries. He serves as the National Urology Research Director for 21st Century Oncology. He is a Fellow of the American College of Surgeons.
Cora Sternberg, MD
Medical oncologist and Clinical Director of the Englander Institute for Precision Medicine, she is a member of the Genitourinary Oncology Program at NewYork-Presbyterian/Weill Cornell Medical Center. A Professor of Medicine at Weill Cornell Medicine, Dr. Sternberg is well-known for her work in developing novel therapies and targeted agents for the treatment of prostate, renal, and bladder cancers.
Christopher Wallis, MD, PhD
Christopher J.D. Wallis, MD, PhD is an Assistant Professor of Urology, Department of Surgery at the University of Toronto. Urologic Oncologist, at Mount Sinai Hospital, Toronto, Ontario, Canada and at the University Health Network, Toronto, Ontario, Canada. He obtained his Doctor of Medicine from the University of British Columbia, his Doctor of Philosophy in Clinical Epidemiology & Health Care Research from the Institute of Health Policy, Management & Evaluation at the University of Toronto, and completed his clinical residency in Urology at the University of Toronto affiliated hospitals. His research focuses on leveraging a variety of epidemiologic techniques to understand and improve care for patients with urologic conditions, particularly prostate cancer.
Evan Yu, MD
Professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine, Member of the Clinical Research Division, Fred Hutchinson Cancer Research Center, Clinical Research Director, Genitourinary Oncology, Seattle Cancer Care Alliance Medical Director, Clinical Research Service, Fred Hutchinson Cancer Research Consortium
Jason Zhu, MD
Medical Oncologist, Atrium Health, Levine Cancer Institute, Charlotte, North Carolina
Karl-Erik Andersson, MD, PhD
Professor at the Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USAKarl-Erik Andersson, MD, PhDwas born and raised in Sweden. He received his medical degree from the University of Lund in 1968, where he subsequently worked as a lecturer in clinical pharmacology. He completed his PhD at the Department of Pharmacology, Lund University, in 1973. In 1975 he obtained a Swedish specialist degree in Internal Medicine and was appointed Professor of Clinical Pharmacology at the University of Odense, Denmark. From 1976 to 1978 he also held the same position at the University of Aarhus, Denmark. From 1978-2006he was Professor and Chairman of the Department of Clinical Pharmacology, University of Lund, Lund, Sweden. He has been visiting professor at the Department of Obstetrics and Gynecology, University of Toronto (1983-1985) and at the Department of Urology, University of Virginia, Charlottesville, USA (1997-1998). From 1993 to 2000 Dr. Andersson was Research Dean of the Medical Faculty at the University of Lund. Since 2006 he is Professor at the Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. Dr. Andersson is a member of many international societies including the American Urological Association, the European Association of Urology, and the International Society for Sexual Medicine. He also serves on the Editorial Boards of several journals, including Journal of Urology, Urology, European Urology, and Neurourology and Urodynamics.Dr. Andersson is Editor-in-Chief of UroToday International Journal. During his career, he has authored more than 700articles in peer-reviewed international journals. His research interests include urogenital and cardiovascular pharmacology and physiology, clinical trials, and regenerative pharmacology.
John M. Fitzpatrick, MD MCh, FRCSI, FC Urol (SA), FRCSGlas, FRCS (1948-2014) Former Co-Editor-in-Chief
Professor and Chairman of the Department of Surgery, Mater Misericordiae Hospital and University College, Dublin, Ireland John M. Fitzpatrick MD MCh, FRCSI, FC Urol (SA), FRCSGlas, FRCS was born and educated in Dublin. He qualified as a doctor in 1971 and became fellow of the Royal College of Surgeons in Ireland in 1975. He received his master's degree in 1976. He is also a fellow of the Royal College of Surgeons of England and of Glasgow. Between 1977 and 1981, Professor Fitzpatrick trained in the St. Peters Hospitals and the Institute of Urology in London. In 1981, Professor Fitzpatrick returned to Dublin as Consultant Urologist and Senior Lecturer in Urology in the Meath and St. James' Hospitals and Trinity College Dublin. In 1986, he was appointed Professor and Chairman of the Department of Surgery in the Mater Misericordiae Hospital and University College Dublin. Professor Fitzpatrick has performed 45 visiting professorships in the United States and other countries throughout the world. He has also given 167 guest lectures throughout the world. He has produced 260 peer-reviewed publications, 74 book chapters, has edited 6 journal editions, and published 12 books. Professor Fitzpatrick is on the editorial board of 25 journals, and is Editor-in-Chief of the British Journal of Urology International. He is President of the Irish Society Urology and is Past President of the British Association of Urological Surgeons. He is a member of the Board of Trustees of the British Urological Foundation and is Chairman of the Scientific Committee of that Foundation. He is an Honorary Fellow of the College of Urologists of South Africa and an honorary member of the British Association of Urological Surgeons and of the American Urological Association as well as an honorary member of the Urological Societies of Australasia, South Africa, Germany, Netherlands, Hungary, Argentina, Greece, and Georgia.
George W. Drach, MD, FACS
Professor of Urology and Director of Outpatient Urology Education, University of Pennsylvania, Philadelphia, PA USA George W. Drach, MD, FACS has served as Professor of Urology and Director of Outpatient Urology Education at the University of Pennsylvania since 1998. From 1996 to 1998, he visited the University of Texas Southwestern Medical School in Dallas as Professor of Urology and directed the Urology Clinic at Parkland Memorial Hospital. During the period 1970 - 1996 he resided at the University of Arizona, where he still holds the title of Professor Emeritus of Surgery/Urology and Founding Chief of Urology. Dr. Drach received his medical degree at Case Western Reserve University, Cleveland, Ohio, and then spent two years in surgical training at the University Hospitals of Cleveland. His training was interrupted by two years of active duty in the US Navy, part of which time was spent as Chief Medical Officer of the aircraft carrier USS Valley Forge. Upon returning to civilian activity, he completed one year of fellowship in urology (endocrinology) and three years of urology residency under Dr. William Boyce at Wake Forest University in North Carolina. He completed his training in 1969, and then completed a medical fellowship at the University of New Mexico. He subsequently moved to his position at the University of Arizona. He is the author of over 112 journal articles, 33 book chapters and 3 books or monographs. He functioned as editor of the American Urological Association (AUA) CME Interactive Education series on Patient Management Problems from 1996 to 2003 and was Chairman of the AUA Publications Committee from 1985 - 1987. He has served nationally as president of many organizations, including the Western Section AUA, the American Board of Urology, the Residency Review Committee for Urology, the Society of University Urologists, the Clinical Society of Genitourinary Surgeons, and the Society for Research on Calculous Kinetics (the ROCK Society). He received the AUA Hugh Hampton Young (outstanding contributions to American urology) and AUA Research Innovator (significant contributions to research) and Certificate of (Lifetime) Achievement awards in 1986, 1990, and 2004, respectively. He served as the Study Monitor for the United States Lithotripter Study (Dornier, Inc. and the National Electrical Manufacturers Assn.) 1982 - 1996, and received the honor of "Father of American Lithotripsy" in 1993. His major research interests include urinary stone disease, urinary and prostatic infections, mechanisms of urinary flow change with aging, and geriatric urology. As a result of this latter interest, he is now Chairman of the AUA Committee for Geriatric Urology, and Past-President of the Geriatric Urological Society. He also serves within the American Geriatric Society as Chairman of the Section on Surgery and Related Medical Specialties.
Alan J. Wein, MD, PhD
Professor and Chair Division of Urology University of Pennsylvania School of Medicine Chief of Urology Hospital of the University of Pennsylvania Philadelphia, PA USA Alan J. Wein, MD, PhD (Hon.) is professor and chair of the Division of Urology at the University of Pennsylvania School of Medicine and Chief of Urology at the Hospital of the University of Pennsylvania. He is a graduate of Princeton University and received his MD from the University of Pennsylvania School of Medicine. He completed training in Surgery and Urology at the University of Pennsylvania including a fellowship at the Harrison Department of Surgical Research. He has been certified and recertified by the American Board of Urology. He was awarded an honorary Ph.D. from the University of Patras, Greece in September 2005. Dr. Wein has been recognized nationally and internationally through his many affiliations and professional memberships which include the American Association of Genitourinary Surgeons, Clinical Society of Genitourinary Surgeons, American Surgical Association, Society of Surgical Oncology, Society of Urologic Oncology, Society of Pelvic Surgeons, Society for Urodynamics and Female Urology, Société Internationale d’Urologie, American Urological Association (AUA) and the Royal Society of Medicine. He is a recipient of the Urodynamics Society Lifetime Achievement Award, the F. Brantley Scott Award of the American Foundation for Urologic Diseases, the Hugh Hampton Young Award of the American Urological Association, and both the Distinguished Service Award and the Distinguished Contribution Award of the American Urological Association. He has been the Ramon Guiteras lecturer at the AUA annual meeting, the AUA lecturer of the Société Internationale d’Urologie and the European Association of Urology and the British Journal of Urology lecturer at the British Association of Urological Surgeons. He has served on and chaired numerous medical committees and consultations both domestically and internationally, and has received numerous awards and honors for excellence in the field of Urology. He has held or does hold editorial positions on many well-respected journals including the Journal of Urology, Survey Section of the Journal of Urology, Neurourology and Urodynamics, Urology, British Journal of Urology International, International Urogynecology Journal, Current Urology Reports, Current Opinion in Urology, Nature Urology and Current Bladder Dysfunction Reports. He has been an editor of the gold standard text in the field, Campbell’s Urology, since 1992 and is currently the editor-in-chief. Dr. Wein has authored or co-authored more than 830 articles and chapters, edited or co-edited 24 books, and has multiple multimedia presentations to his credit. His extensive experience in the field of urology has afforded him the opportunity to participate in academic activities, meetings, and courses as a speaker, faculty member and chairperson. He is a prodigious lecturer with over 600 invited academic activities over the course of his career, including the co-chairmanship of the 1st, 2nd, 3rd and 4th International Consultations on Incontinence. His fields of interest lie in urologic oncology, the physiology and pharmacology of the lower urinary tract, the evaluation and management of voiding function and dysfunction, and urinary incontinence.